Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $55.0, with a high ...

Ionis has entered a licence agreement with Sobi in which the latter obtains exclusive rights to commercialise olezarsen.

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Free Report) has earned an average rating of “Moderate Buy” from the twenty ...

We recently compiled a list of the 12 Most Promising Biotech Stocks According to Wall Street Analysts. In this article, we ...

Ionis Pharmaceuticals and Arrowhead Pharmaceuticals have found a common cause amid their emerging rivalry. | Ionis ...

Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) was upgraded by analysts at StockNews.com to a “sell” rating in a ...

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it has entered into a license agreement under which Sobi® ...

Ionis Pharmaceuticals Inc (NASDAQ:IONS) and Ono Pharmaceutical Co., Ltd entered into a license agreement in which Ono obtains exclusive global rights for the development and commercialization of ...

Carlsbad’s Ionis Pharmaceuticals struck a deal worth up to $940 million with Japan-based Ono Pharmaceutical for its medicine targeting a chronic blood disorder.

Ionis Pharmaceuticals (IONS) announced that it has entered into a license agreement under which Sobi received exclusive rights in countries ...

Ionis Pharmaceuticals (NASDAQ:IONS), a leader in RNA-targeted therapeutics with a market capitalization of $5.3 billion, stands at a critical juncture as it navigates a competitive landscape and ...

JPMorgan lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $45 from $47 and keeps a Neutral rating on the shares. The firm ...